Due to the fact individuals who carry the APOE e4 gene variant seem to have a higher possibility of serious problems, the FDA suggests remaining tested for that gene variant before beginning treatment with lecanemab or donanemab.About pharmacological interventions, three rules suggest no pharmacologic intervention. The usage of cholinesterase inhib